These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 11897208)

  • 1. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
    Kashyap ML; McGovern ME; Berra K; Guyton JR; Kwiterovich PO; Harper WL; Toth PD; Favrot LK; Kerzner B; Nash SD; Bays HE; Simmons PD
    Am J Cardiol; 2002 Mar; 89(6):672-8. PubMed ID: 11897208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
    Grundy SM; Vega GL; McGovern ME; Tulloch BR; Kendall DM; Fitz-Patrick D; Ganda OP; Rosenson RS; Buse JB; Robertson DD; Sheehan JP;
    Arch Intern Med; 2002 Jul; 162(14):1568-76. PubMed ID: 12123399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
    Hunninghake DB; McGovern ME; Koren M; Brazg R; Murdock D; Weiss S; Pearson T
    Clin Cardiol; 2003 Mar; 26(3):112-8. PubMed ID: 12685616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
    Sharma M; Sharma DR; Singh V; Panwar RB; Hira HS; Mohan B; Kumar N; Sharma SK; Gupta R
    Vasc Health Risk Manag; 2006; 2(1):87-93. PubMed ID: 17319473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M;
    Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
    Capuzzi DM; Morgan JM; Weiss RJ; Chitra RR; Hutchinson HG; Cressman MD
    Am J Cardiol; 2003 Jun; 91(11):1304-10. PubMed ID: 12767421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
    Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia.
    Gupta EK; Ito MK
    Heart Dis; 2002; 4(2):124-37. PubMed ID: 11975844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niacin extended-release/lovastatin: combination therapy for lipid disorders.
    Moon YS; Kashyap ML
    Expert Opin Pharmacother; 2002 Dec; 3(12):1763-71. PubMed ID: 12472373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan.
    Lin TH; Voon WC; Yen HW; Huang CH; Su HM; Lai WT; Sheu SH
    Kaohsiung J Med Sci; 2006 Jun; 22(6):257-65. PubMed ID: 16793562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.
    Capuzzi DM; Morgan JM; Carey CM; Intenzo C; Tulenko T; Kearney D; Walker K; Cressman MD
    Prev Cardiol; 2004; 7(4):176-81. PubMed ID: 15539964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data.
    Armstrong EP; Zachry WM; Malone DC
    J Manag Care Pharm; 2004; 10(3):251-8. PubMed ID: 15228376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.
    Insull W; McGovern ME; Schrott H; Thompson P; Crouse JR; Zieve F; Corbelli J
    Arch Intern Med; 2004 May; 164(10):1121-7. PubMed ID: 15159270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
    Morgan JM; Capuzzi DM; Guyton JR
    Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin.
    Gardner SF; Schneider EF; Granberry MC; Carter IR
    Pharmacotherapy; 1996; 16(3):419-23. PubMed ID: 8726600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease.
    Brown BG; Bardsley J; Poulin D; Hillger LA; Dowdy A; Maher VM; Zhao XQ; Albers JJ; Knopp RH
    Am J Cardiol; 1997 Jul; 80(2):111-5. PubMed ID: 9230143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.